Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 238,404 shares of the biopharmaceutical company's stock after acquiring an additional 30,529 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Gilead Sciences were worth $22,021,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences during the fourth quarter worth $28,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter worth $31,000. Stephens Consulting LLC grew its holdings in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,929 shares of company stock valued at $5,644,780 in the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 1.1%

Shares of GILD stock traded up $1.22 on Tuesday, reaching $108.59. 1,574,484 shares of the stock were exchanged, compared to its average volume of 7,701,884. The stock has a market cap of $135.07 billion, a P/E ratio of 293.43, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a 50 day moving average of $105.27 and a two-hundred day moving average of $100.46. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.32) EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.91%. Gilead Sciences's payout ratio is currently 66.53%.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.